Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 17/20 | 0.33 |
| ▸ | CA2 | P00918 | 17/20 | 0.33 |
| ▸ | CA9 | Q16790 | 15/20 | 0.33 |
| ▸ | CA12 | O43570 | 5/20 | 0.32 |
| ▸ | CA7 | P43166 | 5/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.32 |
| ▸ | CA3 | P07451 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 4/20 | 0.32 |
| ▸ | CA6 | P23280 | 4/20 | 0.32 |
| ▸ | CA5A | P35218 | 4/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078198 | 0.93 | TSHR (0.68) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL6582696 | 0.85 | — | — | |
| SCHEMBL576408 | 0.79 | TSHR (0.88) | TSHRUSP2KDM4EALDH1A1LMNA | |
| Busulfan SCHEMBL4764696 | 0.79 | TSHR (1.00) | TSHRUSP2KDM4EALDH1A1LMNA | |
| Busulfan SCHEMBL4373 | 0.79 | TSHR (1.00) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL4298840 | 0.76 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL4952202 | 0.76 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL1335477 | 0.76 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL8592211 | 0.76 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| Busulfan SCHEMBL7195165 | 0.76 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118594777-A | Beneficiation reagent for recycling copper from magnetic iron ore tailings and preparation method thereof | 西北矿冶研究院 | 2024-09-06 | — | — | CN | disclosed |
| CN-107849037-B | Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10336751-B2 | Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336751-B2 | Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3325477-B1 | NOVEL TRICYCLIC 4-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-05-01 | — | — | EP | disclosed |
| EP-3256471-B1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-10093671-B2 | 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3325477-A1 | NOVEL TRICYCLIC 4-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | H. Hoffnabb-La Roche Ag (CH) | 2018-05-30 | — | — | EP | disclosed |
| US-20180134705-A1 | NOVEL TRICYCLIC 4-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-05-17 | — | — | US | disclosed |
| EP-3256471-A1 | NOVEL 2-OXO-6,7-DIHYDROBENZO[A]QUINOLIZINE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-7429598-B2 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| EP-1778653-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Rib-X Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006022794-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20040106631-A1 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-06-03 | — | — | US | disclosed |
| EP-1400244-A1 | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | Warner-Lambert Company LLC (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030229113-A1 | Keratinocyte growth inhibitors and hydroxamic acid derivatives | AKZO NOBEL N.V. (NL) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229113-A1 | Keratinocyte growth inhibitors and hydroxamic acid derivatives | FGF1, FGF2, EGFR | TSHR 1655/4885USP2 3217/4885KDM4E 1263/4885 |
| US-20040106631-A1 | Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors | PDE3A, PDE5A, PDE3B | TSHR 3153/4885USP2 3775/4885KDM4E 2817/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | TSHR 3553/4885USP2 3224/4885KDM4E 3615/4885 |
| US-10093671-B2 | 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, CYP2B6, CYP2A6 | TSHR 2057/4885USP2 2530/4885KDM4E 2436/4885 |
| US-20180134705-A1 | NOVEL TRICYCLIC 4-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP2B6, CYP7A1 | TSHR 1695/4885USP2 3354/4885KDM4E 2062/4885 |
| US-10336751-B2 | Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis B virus infection | CYP2B6, CYP7A1, HAVCR2 | TSHR 1626/4885USP2 3554/4885KDM4E 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.